Artificial intelligence (“AI”) software fully designed a drug intended to treat obsessive-compulsive disorder.
Oxford-based biotech company Exscientia developed an AI system that discovered and developed a pharmaceutical treatment for obsessive-compulsive disorder. The sophisticated software developed the drug, currently known as DSP-1181, using algorithms that checked huge numbers of potential compounds against several relevant factors. It took less than 12 months for the software to develop the drug, which entered human testing this week.